ACI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Albertsons Companies Inc (ACI) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown some positive developments, such as a dividend increase and revenue growth, the financial performance is concerning with a significant net income drop, negative EPS, and declining gross margins. Additionally, technical indicators suggest a bearish trend, and there are no strong trading signals or recent influential trades to support a buy decision. The stock is better suited for monitoring rather than immediate investment.
The technical indicators for ACI show a bearish trend. The MACD is negatively expanding, RSI is neutral at 30.321, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 16.253, with resistance levels at 17.995 and 18.533. The stock has a 70% chance of declining by -2.48% in the next day and -0.51% in the next week, with a potential rebound of 6.04% in the next month.
Dividend increase from $0.15 to $0.17 per share, reflecting improved cash flow.
Revenue growth of 7.73% YoY in Q4
Q4 non-GAAP EPS of $0.48 exceeded expectations.
Net income dropped significantly by -379.86% YoY, resulting in a negative EPS of -0.
Gross margin declined to 27.21, down -0.62% YoY.
$774 million opioid settlement, which could weigh on future financials.
Analysts have lowered price targets, citing muted top-line outlook and pharmacy pricing pressures.
In Q4 2026, Albertsons reported revenue of $20.25 billion, up 7.73% YoY. However, net income dropped to -$480.8 million (-379.86% YoY), and EPS fell to -0.94 (-424.14% YoY). Gross margin also declined to 27.21 (-0.62% YoY). Despite a revenue increase, the company's profitability metrics are concerning.
Analysts have lowered their price targets, with the consensus range now between $20 and $22. Most analysts maintain a Buy or Outperform rating, but they highlight concerns about muted top-line growth, pharmacy pricing pressures, and the impact of the opioid settlement.
